Active pharmacovigilance In the context of the FAMHP’s decision to promote proactive pharmacovigilance, a decision was made at the end of 2007 to encourage healthcare professionals to pay extra attention to adverse effects that arise after taking medicines with a new active ingredient (the “black triangle” project - during
Active pharmacovigilance In the context of the FAMHP’s decision to promote proactive pharmacovigilance, a decision was made at the end of 2007 to encourage healthcare professionals to pay extra attention to adverse effects that arise after taking medicines with a new active ingredient (the “black triangle” project - during
